Search alternatives:
significantly delayed » significantly related (Expand Search), significantly decreased (Expand Search), significantly elevated (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significantly delayed » significantly related (Expand Search), significantly decreased (Expand Search), significantly elevated (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
-
3221
-
3222
-
3223
Changes in the neutrophil count.
Published 2025“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
-
3224
Changes in the platelet count.
Published 2025“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
-
3225
Changes in the white blood cell count.
Published 2025“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
-
3226
Changes in the hemoglobin.
Published 2025“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
-
3227
WBC and ANC on day 7 post-chemotherapy.
Published 2025“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
-
3228
General clinical data of 88 patients with NPC.
Published 2025“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
-
3229
CONSORT participant flow diagram.
Published 2025“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
-
3230
S4 File -
Published 2025“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
-
3231
-
3232
-
3233
Measurement of Na<sup>+</sup> ratio in the TE and blastocyst cross-sectional area in the ouabain-treated group.
Published 2025“…The Na<sup>+</sup> concentration patterns were categorized into two main types: a decrease followed by an increase (Embryo Nos. 1, 3, 7, 9), and no significant change in Na<sup>+</sup> concentration (Embryo Nos. 2, 4, 6, 8). …”
-
3234
-
3235
Summary statistics of key variables.
Published 2024“…We propose that, while there are still agglomeration benefits, the development path followed by cities in developing countries also creates significant agglomeration costs and these act to limit innovation. …”
-
3236
-
3237
-
3238
-
3239
-
3240